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Abstract
The past decade has brought together substantial advances in human genome analysis and a
maturation of understanding of tumor biology. While there is much progress still to be had, there
are now several prominent examples in which tumor-associated somatic mutations have been used
to identify cellular signaling pathways in tumors. This in turn has led to the development of
targeted therapies, with somatic mutations serving as genomic predictors of tumor response and
providing new leads for drug development. There is also a realization that germline DNA variants
can help optimize cancer drug dosing and predict the susceptibility of patients to the adverse side
effects of these drugs; knowledge that ultimately can be used to improve the benefit:risk ratio of
cancer treatment for individual patients.
Mechanistic understanding of the biologic pathways regulating human cancers and the
normal cells from which they are derived has long influenced the management of cancer.
These efforts have shifted from older, cytotoxic therapeutic options toward chemical and
biologic therapies that are precisely designed to target a critical gene or pathway. This has
delivered a degree of tumor control for common cancers, including breast, lung, colorectal,
and extended life and provided cures in some cases of less common cancers, such as
testicular cancer and childhood acute lymphoblastic leukemia. Pathway-driven therapeutics
has significantly improved the outcomes of chronic myelogenous leukemia and
gastrointestinal stromal tumors which may, in the absence of relapse, act as chronic diseases
requiring life-long treatment, akin to diabetes or hypertension management.(1) However,
these advances have come at a cost, both literally and figuratively, with newer treatments
often costing thousands of dollars per month and associated with toxicities that can
negatively affect patient quality of life.
Somatic mutations, variations found within the tumor, and germ-line mutations, heritable
variations found within the individual, may influence disease outcome and/or response to
therapy (Figure 1). These mutations, or cancer biomarkers, can be broadly classified as
prognostic markers, those mainly associated with the course or outcome of a disease, or
predictive markers, which can be used to identify subpopulations of patients who are most
likely to respond to a given therapy. There is opportunity for genetic information to aid both
the selection of effective therapy and the avoidance of treatments with an unacceptable risk
of adverse drug reactions (ADR).
Inherited differences in drug effects were first documented in terms of drug metabolism in
the 1950s,(2, 3) giving rise to the term “pharmacogenetics.” The field has now extended to
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all aspects of drug disposition, including absorption, distribution, and excretion(4), as well
as drug targets and downstream effect mediators. Table 1 outlines some current examples
where genotype is used for the selection of cancer chemotherapy.
Tumor profiling: from discovery science to patient management
Analysis of tumor DNA to guide patient treatment has been used for over 20 years. An acute
lymphoblastic leukemia patient with the presence of a 9:22 chromosomal translocation was
once offered bone marrow transplantation, rather then standard cytotoxic chemotherapy;
more recently these patients would be offered imatinib or other ABL tyrosine kinase
inhibitors. A breast cancer patient with amplification of HER2 might be treated with the
antiHER2 monoclonal antibody trastuzumab or the HER2 tyrosine kinase inhibitor lapatinib.
Thus, focused profiling is becoming part of routine patient management for select cancers
(Table 1) as the lowered costs of high quality DNA sequencing have led to the identification
that some somatic mutations are associated with specific benefits (or lack thereof) from
targeted therapies.
Somatic DNA mutation assessment has positively impacted patient care for a focused
number of cancers. The identification of KRAS mutations in codons 12 or 13 in ~30% of
patients with colon cancer suggests that there is no tumor control benefit, but instead some
toxicity risk, when patients are treated with expensive antibodies targeting EGFR.(5) Lung
cancer, melanoma, and myeloproliferative disorders tend to be sensitive to tyrosine kinase
inhibiutors with mutations in the respective genes EGFR, BRAF, and JAK2. However,
currently there are molecular predictors of efficacy for less than 10% of the FDA approved
cancer drugs.
In addition, cancer cells may mutate and evolve resistance to specific drug treatments
resulting in the proliferation of drug resistant tumors. Beyond the initial patient treatment
setting, there is a lack of personalized cancer medicine trial data on which to guide patient
management decisions. Treatment choices often revert to the use of population average data,
where it is difficult to ascertain the value of therapy for an individual patient. We still need
definitive discovery and validation/replication efforts for anticancer drugs (old and new).
This is particularly true for the older cytotoxic agents, which benefit a meaningful subset of
patients, but do not have the diverse scientific and financial advocacy to assure that genomic
knowledge is being discovered and deployed in a clinically relevant manner.
As sequencing strategies mature and costs are lowered, there has been an increase in the
application of these technologies to tumor profiling.(6, 7) While the current focus is
principally directed towards the identification of somatic DNA mutations, cancer may be
associated with epigenetic traits including specific miRNAs, variations in RNA expression,
methylation patterns and chromatin marks. Currently the most common genetic screening
involves performing a targeted DNA capture, focused on a limited number of relevant
candidate genes, followed by sequencing. (8) This gives a clinical report that may direct
treatment to a signaling pathway that would not be of obvious importance from tumor
histology.
Genomic medicine strategies that can identify and clinically annotate the broad assortment
of actionable variants are needed to justify these efforts. An initial deep sequencing of 145
genes in colorectal and non-small cell lung cancers found somatic mutations in 39/40 (98%)
and 20/24 (83%) of tumors, respectively.(8) More than half (52.5%) of colorectal cancers
and 72% of non-small cell lung cancers contained at least one mutation that has been linked
to a specific chemotherapy approach.(8) Similar data has come from the NCI/NHGRI
Cancer Genome Atlas efforts across tumors from diverse anatomical locations.(6, 7)
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Clinical pharmacogenomic efforts to apply deep sequencing to unveil mechanisms of
sensitivity or resistance to drug therapy are needed; as we do not know the mechanism of
clinical resistance for most anticancer drugs. Sequencing of non-small cell lung cancer
which displayed sensitivity and subsequent resistance to EGFR tyrosine kinase inhibitors led
to the routine use of EGFR sequencing to guide therapeutic choices.(9) Whole exome
sequencing of patients treated with everolimus for advanced bladder cancer revealed that a
specific TSC1 mutation correlated with everolimus sensitivity. Patients with TSC1 mutation
had a longer time until recurrence of tumor (4.1 versus 1.8 months, 11). This loss of function
mutation in TSC1 was subsequently found in 5/96 (5.2%) of advanced bladder cancers,
suggesting that there is a subgroup of patients with this disease for whom everolimus
treatment might offer substantial benefit.
There are limits to how much tissue can be acquired from a clinical biopsy. The practical
issue of low availability of high quality tumor DNA is helping drive analysis from single
gene assays to multigene applications, where more knowledge is derived from the existing
tissue. Also, quality control issues, resulting in uncertain or erroneous identification of
mutations from the use of gene panels or whole genome assessment, may challenge
interpretations of molecular diagnostic results across clinical laboratories. Furthermore, we
need predictive analyses for the 25–80% of cases where variants of unknown significance
are identified in genes that are of interest to a particular tumor. This has been evident in
BRCA1/2 testing, associated with breast cancers. We need to generate both laboratory and
clinical consensus methods to decide which variants in which genes merit clinical action.
(10)
For certain tumor types clinical trial inclusion criteria are starting to focus less on the
anatomical origins and more on the somatic mutations identified within a tumor. The focus
on “driver” mutations controlling tumor invasiveness and its relative therapeutic response
requires screening many patients to find the few that are eligible for a targeted therapy trial.
(11) This is not easily implemented at academic centers as currently a disproportionate load
of patients are referred for experimental therapy without a previously ascertained molecular
profile. This introduces additional time and unsupported expense for somatic sequencing
before a transition into a treatment trial of relevance.
There are also unanticipated issues, such as the current preference for fresh tissue, requiring
a tissue biopsy for the purposes of the somatic profile. Many clinical practice settings do not
have ready access to interventional radiologists for safe biopsy of tumor, nor do they have
personnel trained to properly handle tissue to best retain a tumor’s molecular signature (most
tissues from community oncologists are placed in a formalin-containing fixative and sent to
an outside pathologist). Sequencing efforts targeted at formalin-fixed paraffin embedded
tissue and nucleic acid detection in plasma or identification of circulating tumor cells may
also provide a means to circumvent some of these barriers. Well-designed practical
infrastructure are needed for the application of personalized cancer medicine to ensure that
all the right team members will be trained and ready to provide patient support. Commercial
and academic efforts that focus on disease-specific gene targets, such as the National
Comprehensive Cancer Network or Foundation Medicine, are actively developing the
pathways for application in patient management.(12) As the costs decrease and the
interpretation ability increases, somatic DNA assessment will become a routine part of the
management of cancer.
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The role of germline DNA in optimizing dosing and identifying toxicity risk
of anti-cancer drugs
While the primary focus of cancer genomic research is on the somatically mutated genes
driving tumor growth, inter-patient germline variation can also impact cancer treatment.
Indeed, given that most of oncology supportive care is targeted towards mollifying a
patient’s adverse effects of cancer treatment while eradicating the cancer, genetic variation
can potentially play an important role in the selection and administration of cancer drugs.
There is also an undervalued role of gastrointestinal drug transport and hepatic drug
metabolism on the dose, administration schedule, and route of administration of a drug. The
use of a highly targeted, effective therapy for chronic myelogenous leukemia can be undone
by under dosing, if the drug is metabolized or removed before it encounters the intended cell
or molecular target, setting up a milieu for development of drug resistance.(13)
Pharmacogenomic variation in drug metabolism has been shown to have a role in the
efficacy of certain anticancer therapies such as tamoxifen, an effective anti-estrogen used in
the treatment of hormone receptor positive breast cancer. Bioconversion of tamoxifen to
several active metabolites including endoxifen, its most abundant active metabolite, is
primarily dependent on the highly polymorphic cytochrome P450 2D6 (CYP2D6) enzyme.
In the past, tamoxifen was often co-administered with certain antidepressants for treatment
of antiestrogen-induced hot flashes until it was discovered that the antidepressants blocked
CYP2D6 and the production of endoxifen.(14) Coadministration was abruptly discontinued
in clinical practice, because of the risk that the ‘cure’ of hot flashes was compromising the
effectiveness of the antiestrogen therapy.(15) Clinical trials of endoxifen as a biomarker for
tamoxifen response are now underway.(16)
In addition, approximately 7% of the USA population have a genetic polymorphism or
deletion in CYP2D6, resulting in diminished protein levels and/or function. Over 20
published studies have reported an association between CYP2D6 polymorphisms and breast
cancer outcomes after tamoxifen treatment, although several recent studies suggest that
homozygote variant patients that have no or lower function of CYP2D6 have the poorest
outcome.(17) Studies to determine the appropriate dose of tamoxifen for wild-type patients
(called extensive metabolizers), and the heterozygous patients (intermediate metabolizers),
suggest that the doubling of tamoxifen dose in intermediate metabolizers normalized plasma
endoxifen levels to that observed in extensive metabolizers.(18, 19) This level of data is
consistent with that usually required for FDA prescribing recommendations for dose-
adjustment after organ dysfunction, drug interaction, or age and suggests a relevance to
CYP2D6-guided tamoxifen dosing as a routine part of reducing both interpatient variation
and the risk of underdosing patients with breast cancer.
In most discussions of clinical management of cancer patients the risk/benefit assessment
focuses is on the probability of tumor control from a specific drug, in part because there is a
deficiency, of objective data from which one can assess the patients’ risk of developing
severe adverse drug effects. This deficiency has prompted the launch of genomic discovery
programs that focus on adverse effects of cancer drugs such as sensory peripheral
neuropathy, cardiotoxicity, hearing loss, and other toxicities.(2, 20–23) For example, the
microtubule inhibitor paclitaxel is used to treat breast, lung, and ovarian cancers, but
paclitaxel-induced neuropathy is a common adverse event that often leads to therapeutic
disruption and patient discomfort.(24) However, there are currently no mechanisms for
prospective identification of patients at heightened risk for neuropathy, for whom choices of
drug, administration schedule, and quality of life could be informed.
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Both candidate gene and genome-wide association studies have begun to inform the
prediction of patient risk for neuropathy. A genome-wide association study involved 855
subjects of European ancestry where paclitaxel was administered as part of therapy for
lymph node negative breast cancer. This study identified a single nucleotide polymorphism
in the FGD4 gene, which encodes FGD1-related F-actin binding protein, that was associated
with the onset of sensory peripheral neuropathy in the discovery cohort [Hazard ratio = 1.57;
95% CI 1.30–1.91] and was also observed in a European and African American replication
cohort.(20) As FGD4 is a congenital peripheral neuropathy gene, there is biologic
plausibility to further assess the contribution of genetic variation to the development of
peripheral neuropathy.
Another study identified, a near doubling of increased risk of paclitaxel-induced neuropathy
related to CYP2C8*3 status in breast cancer patients.(21) Although CYP2C8*3 is less
common in African-Americans, a significant association was replicated in direction and
magnitude of effect. The observation of increased risk of paclitaxel-induced neuropathy in
patients who carry the CYP2C8*3 variant across racially distinct patient cohorts suggests
that both pharmacokinetic variables (such as CYP2C8) and biologic variation (such as
FGD4) contribute to patient risk of neuropathy.
The avoidance of chemotherapy-associated morbidity is critical in the context of adjuvant
chemotherapy, where the goal is to kill any stray cancer cells that might have gone
undetected. This is especially important in the treatment of childhood malignancies, as many
patients will survive their cancer and experience the sequelae from adverse drug events for
many years. Cardiomyopathy from anthracycline chemotherapy is a devastating morbidity,
with long-term effects on patient productivity and quality of life. Germline variation
associated with risk of cardiomyopathy has been identified by means of distinct candidate
gene strategies and different patient recruitment strategies. Similar data on germline
pharmacogenomics predictors of cisplatin-associated damage to hearing ototoxicity has also
been reported, providing a mechanism for prospective identification of patients at risk for
this debilitating morbidity.(22)
There are significant limitation to pharmacogenomics discovery for anticancer therapies,
including the challenges of building large patient cohorts for both discovery and validation
purposes. It often takes 7–10 years to construct, conduct, and analyze a clinical trial, which
can then be used for pharmacogenomics discovery. The same is true for a validation cohort,
which is one of the reasons there are so few discovery and replication studies in the
literature. There is also a paucity of information on the heritability of anticancer drug
effects, to help justify the quest for genomic solutions to variability in drug effect. One
approach is the recent use of cell lines from large, multigeneration families, which have
shown a wide variation in heritability of cytotoxicity (10–70%) across 29 commonly
prescribed anticancer drugs, with 66% having greater than 30% heritability.(25) This
presents an opportunity for both prioritization of drugs for assessment and conduct of ex
vivo discovery that will allow precious clinical material to be used for validation studies.
The application of bar coding and robotics have allowed the scale up of cell line
phenotyping to 500–1000 cell lines per project, followed by ex vivo genome-wide
association studies.(25–27) Innovative pharmacogenomics strategies will allow us to more
rapidly capture the relevance of genomic information for rational drug therapy selection
(Figure 2).
Moving into clinical practice
Both replication and validation of pharmacogenomics traits raise challenges. It is often
difficult to characterize, uniformly treat, and systematically evaluate patients in order to
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objectively quantify the drug response phenotype. The standard of care should be to obtain
genomic DNA from all patients entered into clinical drug trials, along with appropriate
consent to permit pharmacogenetic studies. This is now accomplished in most large trials
being conducted by pharmaceutical companies and is routine for some of the NCI clinical
trials groups,(20, 28, 29) but has not yet become standard for academic or foundation-
supported trials (Figure 2).
The challenge is to balance the desire to apply new information and the need to make sure
that there are robust data supporting the idea that acting on a pharmacogenomic marker is in
the best interest of the patient. The reliance on prospective, randomized, controlled trials as
the only way to justify clinical implementation is not practical and guarantees that new
information will have a 5–10 year lag while studies are constructed, conducted, and
interpreted. There is also a disconnection between the funding bodies and the prioritization
of this type of studies, in terms of financial commitment, clinical trial infrastructure, and
ability to rapidly enact new strategies. There have been several efforts to develop ways to
gain confidence in early adoption of pharmacogenomics data, on the basis of consensus-
building among institutions around the application of genetic information to drug therapy.
One such effort is the Clinical Pharmacogenetics Implementation Consortium (CPIC), which
includes participants from >80 institutions across 4 continents.(30) A key element to
programs such as CPIC is the realization that there are some aspects of the medical decision
process, such as drug dosing, that have robust data on which to benefit patients, even as the
field waits for the ‘perfect’ studies that definitively guide therapy at a broader level.
Double standards still exist in clinical decision making, in that a drug interaction may be
accepted as a credentialed, clinically relevant variable and rapidly integrated into clinical
practice, yet the application of genetic data through the exact same mechanism is delayed
due to the need for accumulation of large amounts of prospective data. This is occurring for
CYP2D6 and tamoxifen, CYP3A4 and taxane chemotherapy, and related interactions for
supportive care medications. The standard for drug interaction is influenced by years of
familiarity and no additional time or expense to the patient, but has less functional
predictability than gene deletion in the same pathway. There is a need to come up with a
framework whereby any source of variation in a clinically credentialed pathway can be
moved toward clinical implementation.
The endpoints of pharmacogenomics studies have followed a traditional biomarker scheme,
trying to explain untoward events, identify low utility, define dose selection, or preemptively
predict severe drug reactions. These are important endpoints and should not be neglected in
investigational endeavors. However, there are alternate endpoints that are typically
considered too mundane for inclusion in NIH grants, but are major drivers of early adoption
for new health care modalities. These include avoidance of 30 day readmission rates,
economics of ‘bundled care’, and the prioritization of medication access by a health system
Pharmacy & Therapeutics committee. These endpoints are often accessible through
observational cohorts or electronic health record studies and will likely drive the
implementation of pharmacogenomics into practice.
It is time to be more practical as we move forward. Although substantial progress has been
made in identifying and characterizing pharmacogenetic phenomena, translation of these
data into practical clinical applications remains slow. A variety of factors contribute to this
problem, including a lack of clarity on the amount of data needed to prove clinical utility,
the paucity of interventional pharmacogenetic studies, and unresolved practical
considerations, such as how to establish and implement clear guidelines in departments that
manage cancer. There are also societal factors at play, including acceptance of widespread
genetic testing as well as implications for insurance coverage and liability. These issues will
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need to be explored and addressed before the promise of genetically customized medicine
can become reality.
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Figure 1. Attention must be paid to both tumor and host
cancer pharmacogenomic variation in both the tumor (somatic changes) and normal tissues
(germline variants) influence the treatment of cancer patients.
McLeod Page 8













Figure 2. A multidimensional strategy is required
A blend of in vitro, ex vivo, and in vivo strategies are needed to more rapidly move the
promise of pharmacogenomics into application.
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Pharmacogenomic DNA markers in clinical use for chemotherapy or supportive care of cancer patients
Germline Somatic Drugs Effect
Thiopurine methyltransferase -------- Mercaptopurine, Thioguanine Neutropenia risk
UDP-glucuronosyltrans ferase 1A1 -------- Irinotecan, Nilotinib Neutropenia risk; underdosing
risk
Glucose-6-phosphate dehydrogenase -------- Rasburicase Anemia
Cytochrome P450 2D6 -------- Codeine, oxycodone; Tamoxifen Altered pain control; Altered
tumor control
-------- Janus Kinase 2 (JAK2) Ruxolitinib Altered drug activity
-------- Human Epidermal Growth










Lack of drug activity
Abelson murine leukemia viral
oncogene homolog 1 (ABL)
Imatinib, Dasatinib, Nilotinib Altered drug activity
-------- v-kit Hardy-Zuckerman 4 feline
sarcoma viral oncogene
homolog (KIT)
Imatinib Altered drug activity
-------- Human Epidermal Growth
Factor Receptor 2 (HER2)
Lapatinib Trastuzumab Enhanced drug activity
-------- v-Raf murine sarcoma viral
oncogene homolog B1 (BRAF)
Vemurafenib Enhanced drug activity
-------- Anaplastic lymphoma receptor
tyrosine kinase (ALK)
Crizotinib Altered drug activity
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